BioCrea, the first-in-class CNS drug discovery specialist, has announced that CEO Dr Tom Kronbach will present at BioTrinity 2014, Europe’s leading Biopartnering and Investment Conference, to be held on 12-14 May in London. Kronbach will be presenting on May 13.
"This is a wonderful opportunity for BioCrea to present its lead programmes and novel discovery platforms to over 30 major pharmaceutical companies," said Kronbach. "In partnering terms, we will talk about our two unique proprietary small molecule programmes: long-term acting GABAA positive allosteric modulators (LT GABAA PAMs) to treat epilepsy plus autism; and NMDA receptor 2B (NR2B) negative allosteric modulators (NAMs) to treat depression. Both programmes are expected to reach the IND-enabling study phase later this year."
Founded and produced by OBN, BioTrinity has become the ‘must attend’ life sciences conference for emerging European companies, investors and partners. The conference is now in its eighth year. BioTrinity has grown rapidly over recent years, and is now located in London to accommodate increased interest. More than 1,000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to meet one-on-one, attend panel discussions and workshops, or browse the company showcases.
German organisation BioCrea has established a number of programmes in neurological and psychotic disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimisation approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).
